Frances Sé Maria, Murray Louise, Nicklin Emma, Velikova Galina, Boele Florien
Patient-Centred Outcomes Research, Leeds Institute of Medical Research at St James's, St James's University Hospital, University of Leeds, Leeds, UK.
Department of Clinical Oncology, Leeds Cancer Centre, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Neurooncol Adv. 2024 Jan 19;6(1):vdae007. doi: 10.1093/noajnl/vdae007. eCollection 2024 Jan-Dec.
Meningiomas account for ~25% of all primary brain tumors. These tumors have a relatively favorable prognosis with ~92% of meningioma patients surviving >5 years after diagnosis. Yet, patients can report high disease burden and survivorship issues even years after treatment, affecting health-related quality of life (HRQOL). We aimed to systematically review the literature and synthesize evidence on HRQOL in meningioma patients across long-term survival, defined as ≥2 years post-diagnosis.
Systematic literature searches were carried out using Medline, EMBASE, CINAHL, PsycINFO, and Web of Science Core Collection. Any published, peer-reviewed articles with primary quantitative, qualitative, or mixed-methods data covering the physical, mental, and/or social aspects of HRQOL of meningioma survivors were included. A narrative synthesis method was used to interpret the findings.
Searches returned 2253 unique publications, of which 21 were included. Of these, = 15 involved quantitative methodology, = 4 mixed methods, and = 2 were qualitative reports. Patient sample survival ranged from 2.75 to 13 years. HRQOL impairment was seen across all domains. issues included persevering symptoms (eg, headaches, fatigue, vision problems); issues comprised emotional burden (eg, high prevalence of depressive symptoms and anxiety) and cognitive complaints; issues included role limitations, social isolation, and affected work productivity. Due to study heterogeneity, the impact of treatment on long-term HRQOL remains unclear.
The findings from this review highlight the areas of HRQOL that can be impacted in long-term survivorship for patients with meningioma. These findings could help raise awareness among clinicians and patients, facilitating support provision.
脑膜瘤占所有原发性脑肿瘤的约25%。这些肿瘤的预后相对较好，约92%的脑膜瘤患者在诊断后存活超过5年。然而，即使在治疗多年后，患者仍可能报告疾病负担和生存问题严重，影响与健康相关的生活质量（HRQOL）。我们旨在系统回顾文献，并综合关于诊断后≥2年的长期生存的脑膜瘤患者HRQOL的证据。
使用Medline、EMBASE、CINAHL、PsycINFO和Web of Science核心合集进行系统文献检索。纳入任何已发表的、经过同行评审的文章，这些文章包含关于脑膜瘤幸存者HRQOL的身体、心理和/或社会方面的主要定量、定性或混合方法数据。采用叙述性综合方法来解释研究结果。
检索返回2253篇独特的出版物，其中21篇被纳入。其中，15篇涉及定量方法，4篇为混合方法，2篇为定性报告。患者样本的生存时间从2.75年到13年不等。在所有领域均观察到HRQOL受损。身体问题包括持续存在的症状（如头痛、疲劳、视力问题）；心理问题包括情感负担（如抑郁症状和焦虑的高患病率）和认知主诉；社会问题包括角色限制、社会隔离和工作效率受影响。由于研究的异质性，治疗对长期HRQOL的影响仍不清楚。
本综述的结果突出了脑膜瘤患者长期生存中可能受到影响的HRQOL领域。这些结果有助于提高临床医生和患者的认识，促进支持措施的提供。
